Lipoprotein (A) biomarkers for clinical practice
- VernacularTitle:Липопротейн (A) эмнэлзүйн практикт ашиглах биомаркер
- Author:
Sodgerel B
1
;
Anudari I
1
;
Buyandelger J
1
Author Information
1. Institute of Medical Sciences
- Publication Type:Review
- Keywords:
Lipoprotein (a);
genetics, apolipoprotein (a);
plasminogen;
atherothrombosis;
сardiovascular diseases risk factors;
bibliometrics
- From:Mongolian Medical Sciences
2022;202(4):38-47
- CountryMongolia
- Language:Mongolian
-
Abstract:
A lot of factors can cause coronary heart disease and ischemic stroke including external risk factors such as tobacco, alcohol consumption, decreased physical activity, obesity while arterial maintenance, high blood sugar, increased LDL are internal risk factors. We can reduce our external risk factors by changing our lifestyle. Recent studies have shown increased blood Lp(a) levels are independent risk factor for cardiovascular disease. After 1987, the number of publications has increased since the cDNA homology sequence of Lp(a) and plasminogen 2 was identified. Lp(a) is protein complex consisting from apolipoprotein, phospholipid, free cholesterol, cholesterol esters and tryglyceride. Apoliprotein is a lipid that binds with lipoprotein. Lipoproteins have water-soluble and fat-soluble parts, and those parts bind to lipids and are transported in the bloodstream.How is elevated Lp(a) a risk factor for cardiovascular disease? How much does lowering Lp(a) reduce CVD risk factors? If high Lp(a) concentrations are present, mitigation measures are outlined below.
- Full text:2022-202(4)-38-47.pdf
